These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 6676389

  • 21. Elcatonin attenuates disuse osteoporosis after fracture fixation of tubular bone in rats.
    Ji Z, Shi C, Huang S, Dang X, Wang K, Lan B.
    J Orthop Surg Res; 2015 Jul 03; 10():103. PubMed ID: 26138716
    [Abstract] [Full Text] [Related]

  • 22. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment.
    Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M.
    J Bone Miner Metab; 2005 Jul 03; 23(2):167-73. PubMed ID: 15750696
    [Abstract] [Full Text] [Related]

  • 23. Studies of drug delivery systems for a therapeutic agent used in osteoporosis. I. Pharmacodynamics (hypocalcemic effect) of elcatonin in rabbits following rectal administration of hollow-type suppositories containing elcatonin.
    Watanabe Y, Mizufune Y, Kubomura A, Kiriyama M, Utoguchi N, Matsumoto M.
    Biol Pharm Bull; 1998 Nov 03; 21(11):1187-90. PubMed ID: 9853410
    [Abstract] [Full Text] [Related]

  • 24. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
    Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J.
    N Engl J Med; 1993 Jun 17; 328(24):1747-52. PubMed ID: 7684512
    [Abstract] [Full Text] [Related]

  • 25. Effect of synthetic eel calcitonin, elcatonin, on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in rats.
    Aoki M, Mori A, Nakahara T, Sakamoto K, Ishii K.
    Eur J Pharmacol; 2012 Dec 05; 696(1-3):62-9. PubMed ID: 23001015
    [Abstract] [Full Text] [Related]

  • 26. [Hypocalcemic effect of elcatonin in mouse models for humoral hypercalcemia of malignancy].
    Isogai Y, Hori M.
    Nihon Yakurigaku Zasshi; 1995 Apr 05; 105(4):199-208. PubMed ID: 7774857
    [Abstract] [Full Text] [Related]

  • 27. Postmenopausal and senile osteoporosis: current concepts of etiology and treatment.
    Riggs BL.
    Endocrinol Jpn; 1979 Jun 05; 26(Suppl):31-41. PubMed ID: 467347
    [Abstract] [Full Text] [Related]

  • 28. [Prevention of post-ovariectomy osteoporosis in the rat. Comparative study of synthetic salmon calcitonin and eel calcitonin aminosuberic analogue].
    Gnudi S, Zati A, Giardino R, Fini M, Pratelli L, Orlandi M, Figus E.
    Minerva Endocrinol; 1993 Sep 05; 18(3):123-7. PubMed ID: 8183179
    [Abstract] [Full Text] [Related]

  • 29. [Behavior of urinary excretion of cyclic AMP in post-menopausal osteoporosis during therapy with salmon calcitonin].
    Nuti R, Galli M, Righi GA, Turchetti V, Campagna MS, Franci B.
    Minerva Med; 1982 May 07; 73(19):1283-9. PubMed ID: 6281691
    [Abstract] [Full Text] [Related]

  • 30. [The efficacy of combined use of 1 alpha-hydroxyvitamin D3 with calcium supplements in the treatment of osteoporosis].
    Yoshikawa S, Ohno A, Moro K, Matsumoto M, Nemoto H, Seki H, Kaneko N, Hosokawa O, Ishijima H.
    Nihon Seikeigeka Gakkai Zasshi; 1988 Aug 07; 62(8):723-32. PubMed ID: 3235892
    [Abstract] [Full Text] [Related]

  • 31. Effect of calcitonin and vitamin D in osteoporosis.
    Palmieri GM, Pitcock JA, Brown P, Karas JG, Roen LJ.
    Calcif Tissue Int; 1989 Sep 07; 45(3):137-41. PubMed ID: 2505903
    [Abstract] [Full Text] [Related]

  • 32. Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia.
    Matsumoto T, Nagata N, Horikoshi N, Adachi I, Ohashi Y, Ogata E.
    J Int Med Res; 2002 Sep 07; 30(3):230-43. PubMed ID: 12166339
    [Abstract] [Full Text] [Related]

  • 33. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW, Yeung SS.
    J Clin Endocrinol Metab; 1996 Mar 07; 81(3):1232-6. PubMed ID: 8772604
    [Abstract] [Full Text] [Related]

  • 34. Inhibitory effect of [Asu1 . 7]-eel calcitonin on glucagon-induced glycogenolysis in perfused rat liver.
    Mine T, Kimura S, Ogata E.
    Horm Metab Res; 1983 Mar 07; 15(3):139-43. PubMed ID: 6303930
    [Abstract] [Full Text] [Related]

  • 35. Elcatonin injections suppress systemic bone resorption without affecting cortical bone regeneration after drill-hole injuries in mice.
    Katae Y, Tanaka S, Sakai A, Nagashima M, Hirasawa H, Nakamura T.
    J Orthop Res; 2009 Dec 07; 27(12):1652-8. PubMed ID: 19489046
    [Abstract] [Full Text] [Related]

  • 36. Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).
    Yamamoto K, Maeyama I, Kishimoto H, Morio Y, Harada Y, Ishitobi K, Ishikawa J.
    Endocrinol Jpn; 1983 Oct 07; 30(5):651-6. PubMed ID: 6423374
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effectiveness of the elcatonin transdermal system for the treatment of osteoporosis and the effect of the combination of elcatonin and active vitamin D3 in rat.
    Ogiso T, Iwaki M, Tanino T, Paku T.
    Biol Pharm Bull; 1993 Sep 07; 16(9):895-8. PubMed ID: 8268857
    [Abstract] [Full Text] [Related]

  • 39. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D, Gonnelli S, Camporeale A, Batignani T, Nardi P, Ianes A, Gennari C.
    Minerva Endocrinol; 1989 Sep 07; 14(3):169-76. PubMed ID: 2695815
    [Abstract] [Full Text] [Related]

  • 40. [Antihypertensive action of elcatonin].
    Takayanagi N, Tozuka T, Toda N.
    Nihon Yakurigaku Zasshi; 1983 Nov 07; 82(5):383-93. PubMed ID: 6671629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.